Azilsartan medoxomil

Chemical formula: C₂₅H₂₀N₄O₅  Molecular mass: 568.534 g/mol  PubChem compound: 135409642

Active ingredient description

Azilsartan medoxomil is an orally active prodrug that is rapidly converted to the active moiety, azilsartan, which selectively antagonises the effects of angiotensin II by blocking its binding to the AT1 receptor in multiple tissues. Angiotensin II is the principal pressor agent of the RAAS, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code Group title Classification
C09CA09 Azilsartan medoxomil C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09C Angiotensin II antagonists, plain → C09CA Angiotensin II antagonists, plain
Discover more medicines within C09CA09

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title Information Source Document Type  
EDARBYCLOR Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
EDARBI Tablet European Medicines Agency (EU) MPI, EU: SmPC

Structural formula

Graphic representation of the active ingredient's molecular structure

External identifiers

CAS Substance: 863031-21-4
DrugBank Drug: DB08822
KEGG Drug: D08067
PubChem Compound: 135409642
RxNorm Ingredient: 1091642
SNOMED-CT Concept: 449561004
Azilsartan medoxomil (substance)
UNII Identifier: LL0G25K7I2
AZILSARTAN MEDOXOMIL

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.